Trials / Recruiting
RecruitingNCT05400317
A Study to Evaluate the Efficacy and Safety of AD-218
A Randomized, Double-blinded, Active-controlled, Multicenter Phase 3 Clinical Trial and Open-label, Extension Study to Evaluate the Efficacy and Safety of AD-218 in Patients with Mixed Dyslipidemia
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 520 (estimated)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-218
Detailed description
Condition or disease : Mixed Dyslipidemia Treatment Drug : AD-218, AD-218A, Placebo of AD-218, Placebo of AD-218A
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AD-218 | PO, Once daily(QD), 12weeks |
| DRUG | AD-218A | PO, Once daily(QD), 12weeks |
Timeline
- Start date
- 2022-07-27
- Primary completion
- 2026-03-31
- Completion
- 2026-06-30
- First posted
- 2022-06-01
- Last updated
- 2025-02-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05400317. Inclusion in this directory is not an endorsement.